Company Encyclopedia
View More
name
China Universal Hang Seng Biotechnology Technology ETF(QDII)
513280.SH
News
View More

China Greenlights World’s First Dual-Immunotherapy for Colon Cancer Ahead of Surgery

China's drug regulator has approved Innovent Biologics' Daboxin® (Ipilimumab N01 Injection) for use with another monoclonal antibody as a pre-surgery immunotherapy for colon cancer. This is the world's first approved dual-immunotherapy neoadjuvant regimen for resectable stage IIB to III MSI-H/dMMR colon cancer. The treatment aims to improve outcomes and reduce chemotherapy reliance for patients less responsive to traditional treatments.

Yicai·
HK
01801
+0.06%
Yicai·
HK
01801
+0.06%

Innovent Biologics Wins NMPA Approval for First Domestic CTLA-4 Antibody TABOSUN in Colon Cancer

Innovent Biologics Inc. has received approval from China's NMPA for TABOSUN® (ipilimumab N01 injection), the first domestic CTLA-4 monoclonal antibody, for use with TYVYT® in treating stage IIB-III MSI-H/dMMR colon cancer. This marks the first global approval for such a neoadjuvant treatment, addressing a significant unmet need in China.

Reuters·
HK
01801
+0.06%
Reuters·
HK
01801
+0.06%
© 2025 Longbridge｜Disclaimer